Hydrogel-Based Scaffolds for Bone Regeneration – Comprehensive Study Notes

Publication Details

  • Article: “Hydrogel-Based Scaffolds: Advancing Bone Regeneration Through Tissue Engineering”
  • Journal: Gels 2025, Volume 11, Article 175.
  • DOI: https://doi.org/10.3390/gels11030175
  • Publication timeline:
    • Received: 29 Jan 2025
    • Revised: 21 Feb 2025
    • Accepted: 25 Feb 2025
    • Published: 27 Feb 2025
  • Open‐access, CC-BY 4.0 licence.
  • Authors & affiliations include Autonomous University of Sinaloa (Mexico) and Autonomous University of Chihuahua (Mexico).

Abstract & Scope

  • Bone tissue engineering (BTE) seeks alternatives to autografts/allografts to repair defects.
  • Hydrogels (HGs) are 3-D hydrophilic polymer networks offering:
    • Biocompatibility, biodegradability, tunable mechanics.
    • Capacity to encapsulate/deliver bioactives.
  • Current focus: functionalising natural & synthetic HGs with growth factors/peptides to enhance osteoinduction & osteoconduction.
  • Goals: optimise composition, structure, degradation, mechanical support for long-term stability.

Introduction to Tissue Engineering

  • Multidisciplinary field using cells, biomaterials & signalling molecules to renovate, replace, regenerate tissues.
  • Key elements (“tissue-engineering triad”):
    1. Scaffold (structural support)
    2. Growth factors (signal)
    3. Cells (builders)
  • Biomaterials categories: bio-polymers, bio-metals, bio-ceramics, bio-composites; also classified by consistency (rigid vs hydrogel).
  • Optimal scaffold degradation rate ≈ rate of new bone formation.

Bone Biology

Structure & Composition

  • Two architectures:
    • Cortical (≈80 %): dense, slow‐remodelling, mechanical strength.
    • Trabecular (≈20 %): porous, elastic, high turnover.
  • Matrix:
    • Organic: mainly type I collagen (COL-I); minor COL-III; non-collagenous proteins (fibronectin, OCN, OPN, osteonectin).
    • Mineral: hydroxyapatite Ca<em>3(PO</em>4)<em>2⋅(OH)</em>2Ca<em>3(PO</em>4)<em>2\cdot(OH)</em>2 nanocrystals.

Remodelling Cycle (5 stages)

  1. Osteoclast precursor activation
  2. Resorption by osteoclasts
  3. Reversal (4–5 weeks)
  4. Formation by osteoblasts
  5. Termination → osteocytes.

Bone Healing Pathways

  • Primary (gap < 0.1 mm) – direct ossification.
  • Secondary (gap 0.1 mm – 2× bone dia.) – callus formation, predominant clinically.
  • Direct (intramembranous) vs indirect (endochondral) healing.
  • Cytokine & GF cascade: IL-1, IL-6, TNF-α, VEGF, FGF, PDGF, TGF-β, BMP-2; macrophage M1→M2 transition critical.

Clinical Need & Epidemiology

  • ≈178 M fractures in 2019 (33 % rise since 1990).
  • 5 % progress to non-union.
  • >4 M bone‐related procedures annually; bone void market ≈ USD 2.8 B.
  • Autografts (iliac crest) valued for osteoconductive, osteoinductive & osteogenic properties but carry donor-site morbidity.

Hydrogel-Based Scaffolds (HGs)

Core Advantages

  • ECM-like porosity & water content (1–20 % dry mass).
  • Injectable/minimally invasive; self-setting in situ.
  • Permeability for O₂/nutrients; waste removal.
  • Customisable via cross-linking to control degradation & release kinetics.

Cross-Linking Modes

  • Physical (non-covalent): temperature, pH, ionic, H-bonding, hydrophobic, electrostatic.
  • Chemical (covalent): photo-, enzymatic, click, glutaraldehyde, etc.
Physically Responsive HGs
  • Temperature-, pH-, photo-, glucose-, electro/magnetic-responsive.
Chemically/Biologically Responsive HGs
  • Bio-functional peptide cross-linkers; protease or ROS-cleavable links.

Key Selection Criteria

  1. Immune modulation (reduce heterotopic ossification, fibrotic encapsulation).
  2. Minimal inflammation (promote M2 macrophages via alginate/amelogenin, curcumin-ceria nanoparticles, MP196 peptide).
  3. Mechanical match (stiffness range 0.1–>100 kPa for MSC fate).
  4. Porosity (bones 5–90 %, pores 0.1–2000 µm) → optimise nutrient diffusion.
  5. Water uptake (contact angle assays) for cell adhesion/migration.
  6. Bioactivity: antibacterial, ROS-scavenging, ion/drug release.

Physical Properties Summary

  • Cross-linking agents: resveratrol, tannic acid enhance PVA gelation.
  • Stiffness examples:
    • Gelatin/PEGDA/DMEMA HG >170\,kPa modulus.
    • Chitosan–hyaluronic blends: 576→7369 Pa576\to7369\,Pa tune cell proliferation.
  • Porosity vs HA load: 2 % nanohydroxyapatite → <100 µm pores yet weaker mechanics.

Bioactive Properties & Drug Delivery

  • Controlled long-term release (e.g.
    • GelMA–chitosan–aspirin HG → anti-inflammatory, osteoinductive > 24 h).
  • Osteogenic enhancement via BAG-amine nanoparticles in PEG HG (RUNX2↑, ALP↑).
  • Graphene-oxide alginate microgels maintain single-MSC viability/proliferation.

Categories of Bone-Regenerative HGs

1. Natural Polymers

Protein-Based
  • Collagen: RGD-rich, enzymatically cross-linked; drawbacks—fast degradation, weak.
  • Fibrin: injectable, minimal inflammation; rapid biodegradation.
  • Gelatin: negative charge; carrier for BMP-2, black phosphorus; visible-light cross-linkable.
  • ECM-derived gels: bone/demineralised matrix; retain growth factors; antibacterial.
  • Silk/Silk fibroin: self-assembly; requires bioactive fillers (Laponite, ACP, PRP) for osteoconduction.
Carbohydrate-Based
  • Agarose: self-gelling ≤ 35 °C; porous, antibacterial.
  • Alginate: anionic α-L−G\alpha\text-L-G /β-D−M\beta\text-D-M units; Ca²⁺ gelation; RGD-coupling boosts adhesion.
  • Hyaluronic acid: injectable, anti-inflammatory; Nb-BAG or Fmoc-FF peptides → RUNX2 pathway.
  • Chitosan: polycationic, mucoadhesive; glycerol-phosphate for thermo-gelation; BMP-2, TGF-β3 carriers.
  • Dextran: modifiable neutral glucan; tyramine conjugate HG + bFGF accelerates femur healing.

2. Synthetic Polymers

  • PEG: photopolymerised; RGD/BMP-2 functionalisation; stiffness tunable.
  • PPF: injectable covalent gel; antibiotic-loaded for infection + bone formation.
  • PCL: 3-D printed; Mg or Zn doping; sustained BMP-2 release 21 d.
  • PVA: hydrophilic; resveratrol self-cross-linking improves ALP, mineralisation.
  • γ\gamma-PGA: bacterial polyacid; collagen/γ-PGA/BMP-2 HG healed mouse calvaria in 4 wks.

Functional Classification

  • Osteoconductive HGs: native ECM/gelatin/collagen/agarose.
  • Osteoinductive HGs: base + growth factors/peptides (BMP-2, PDGF, etc.).
  • Osteogenic HGs: incorporate osteoprogenitor cells (MSCs, DPSCs, etc.).

Functionalisation with Bioactive Molecules

Growth Factors

  • BMP-2/-9: potent MSC-osteoblast induction; BMP-2\text{BMP-2} 250 µg mL⁻¹ clinical dose; ectopic risk mitigated by HA/gelatin (600 ng sufficient).
  • PDGF-BB: FDA-cleared; platelet lysate HG ↑RUNX2, OCN; PLLA core-shell nanofibers for sustained release.
  • bFGF (FGF-2): initiates angiogenesis; prevents epithelial downgrowth; 0.5–2 µg on collagen membranes healed rat mandible.

Peptides

  • RGD: integrin-binding; improves adhesion but excess hinders migration.
  • LL-37: cationic antimicrobial; recruits STRO-1⁺ MSCs; sequential LL-37→W9 enhances osteogenesis.
  • Osteogenic Growth Peptide (OGP 10-14): up-regulates BMP-2, OCN, OPN in GelMA.
  • MP196, PTHrP fragments, YAP-activating sequences explored for immune modulation & mechanotransduction.

Pre-Clinical Models & Evaluation

  • Rodents (Sprague Dawley, Wistar, C57BL/6J) dominate due to 99 % genomic homology, cost, rapid breeding.
  • Larger models: New Zealand rabbits, cynomolgus monkeys for translational data.
  • Defect sites: calvaria, tibia, femur, mandible, alveolar, radius; critical-size established per species.
  • Assessment tools:
    • μ\muCT densitometry & 3-D bone volume fraction.
    • Histology (H&E, Masson), immunohistochemistry.
    • Mechanical push-out/compression tests.
    • Gene/protein assays: ALP, RUNX2, COL-I, OCN, OPN, OSX.
    • Live/dead, MTT, YAP activation, macrophage M1/M2 markers.

Challenges & Adverse Effects

  • Ectopic ossification (BMP-2 over-dose) → formulate with ceramic fillers for controlled release.
  • Foreign body response → PEG often encapsulated; alternating Glu-Lys HG resists fibrosis 6 mo.
  • Mechanical weakness of injectable HGs; solutions: Mg-phosphate cement, nanofillers (BAG, chitin whiskers).
  • Synchronising degradation with tissue formation; enzymatic (collagenase) or ROS-responsive links.
  • Peptide/ GF cost & stability; need tunable cross-link density, protease-cleavable motifs.

Future Perspectives

  • 4-D bioprinting: stimuli-responsive bio-inks + cell-laden HGs for patient-specific, shape-morphing implants.
  • Smart HGs responding to pH, temp, electric/magnetic fields for on-demand drug delivery.
  • Integrating rigid 3-D printed lattices (PCL, PLA) with soft HGs → load-bearing hybrid constructs.
  • Regulatory translation: harmonise ISO 10993 biocompatibility with long-term immunological profiling.

Key Equations & Figures (text-only)

  • Hydroxyapatite: (Ca<em>3(PO</em>4)<em>2⋅(OH)</em>2)(Ca<em>3(PO</em>4)<em>2\cdot(OH)</em>2)
  • Stiffness (Young’s modulus) range for MSC fate: 0.1\,kPa \rightarrow >100\,kPa
  • Porosity range in human bone: 5%→90%5\% \rightarrow 90\%; pore diameters 0.1 μm→2000 μm0.1\,\mu m \rightarrow 2000\,\mu m.